230 related articles for article (PubMed ID: 12139425)
21. Patterns of isolation of common gram positive bacterial pathogens and their susceptibilities to antimicrobial agents in Jimma Hospital.
Gebreselassie S
Ethiop Med J; 2002 Apr; 40(2):115-27. PubMed ID: 12240573
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Gram-positive bacterial infection in patients following liver transplantation.
Li H; Yu DL; Ren L; Zhong L; Peng ZH; Teng MJ
Chin Med J (Engl); 2012 Jul; 125(14):2417-21. PubMed ID: 22882913
[TBL] [Abstract][Full Text] [Related]
23. Evolution of antibiotic resistance in gram-positive pathogens.
Marchese A; Schito GC; Debbia EA
J Chemother; 2000 Dec; 12(6):459-62. PubMed ID: 11154025
[TBL] [Abstract][Full Text] [Related]
24. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
25. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics.
Chua K; Howden BP
Curr Opin Infect Dis; 2009 Dec; 22(6):525-34. PubMed ID: 19738465
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).
Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
28. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
29. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Denys GA; Koch KM; Dowzicky MJ
Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
[TBL] [Abstract][Full Text] [Related]
30. Microbiology of antibiotic resistance in Staphylococcus aureus.
Appelbaum PC
Clin Infect Dis; 2007 Sep; 45 Suppl 3():S165-70. PubMed ID: 17712742
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin: understanding its past and preserving its future.
Levine DP
South Med J; 2008 Mar; 101(3):284-91. PubMed ID: 18364659
[TBL] [Abstract][Full Text] [Related]
32. Vancomycin resistance: are there better glycopeptides coming?
Linden PK
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
[TBL] [Abstract][Full Text] [Related]
33. [Rapid and reliable detection of multiresistent Staphylococcus aureus (MRSA) by multiplex PCR].
Domann E; Hossain H; Füssle R; Chakraborty T
Dtsch Med Wochenschr; 2000 May; 125(20):613-8. PubMed ID: 11256043
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents.
Rossolini GM; Mantengoli E; Montagnani F; Pollini S
Curr Opin Microbiol; 2010 Oct; 13(5):582-8. PubMed ID: 20846900
[TBL] [Abstract][Full Text] [Related]
35. Novel antimicrobial agents against multi-drug-resistant gram-positive bacteria: an overview.
Giannakaki V; Miyakis S
Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):182-8. PubMed ID: 23016758
[TBL] [Abstract][Full Text] [Related]
36. Novel agents for resistant Gram-positive infections--a review.
Strahilevitz J; Rubinstein E
Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
[TBL] [Abstract][Full Text] [Related]
37. Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
Boneca IG; Chiosis G
Expert Opin Ther Targets; 2003 Jun; 7(3):311-28. PubMed ID: 12783569
[TBL] [Abstract][Full Text] [Related]
38. Evolving resistance among Gram-positive pathogens.
Munita JM; Bayer AS; Arias CA
Clin Infect Dis; 2015 Sep; 61 Suppl 2(Suppl 2):S48-57. PubMed ID: 26316558
[TBL] [Abstract][Full Text] [Related]
39. Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity.
Ginzburg E; Namias N; Brown M; Ball S; Hameed SM; Cohn SM
Int J Antimicrob Agents; 2000 Nov; 16 Suppl 1():S39-42. PubMed ID: 11137408
[TBL] [Abstract][Full Text] [Related]
40. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.
Rivera AM; Boucher HW
Mayo Clin Proc; 2011 Dec; 86(12):1230-43. PubMed ID: 22134942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
